Diaceutics (LON:DXRX) Issues Quarterly Earnings Results

Diaceutics (LON:DXRX) announced its quarterly earnings data on Tuesday. The company reported GBX (3.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%.

Diaceutics Stock Performance

Shares of LON DXRX traded up GBX 1.50 during mid-day trading on Thursday, hitting GBX 193. The company had a trading volume of 986,367 shares, compared to its average volume of 209,176. The company has a market capitalization of £163.78 million, a price-to-earnings ratio of 1,754.55 and a beta of 0.88. Diaceutics has a 1 year low of GBX 125 and a 1 year high of GBX 197. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. The stock’s 50-day moving average price is GBX 148.17 and its 200-day moving average price is GBX 151.55.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.